EC launches public consultation on content of site master file
This article was originally published in The Gold Sheet
The European Commission is consulting the public on Part III of the EU GMPs, which describes how manufacturers should prepare site master files. The deadline for public comment is March 31. The site master file concept has been developed by the Pharmaceutical Inspection Cooperation Scheme and has become a standard expectation of EU authorities. Following a recent revision of the explanatory notes by PIC/S, it has been proposed that the status of the site master file is more formally linked to the EU regulatory framework. The site master file should contain specific information about the quality management policies and activities of the company, the production site and the quality control of pharmaceutical manufacturing operations carried out at the named site and any closely integrated operations at adjacent and nearby buildings. When submitted to a regulatory authority, the site master file "should provide clear information on the manufacturer's GMP-related activities that can be useful in general supervision and in the efficient planning and undertaking of GMP inspections.
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.